Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has signed a contract with Konica Minolta Co., Ltd (Konica Minolta) to acquire Konica Minolta's new high-sensitivity biomarker measurement technology that uses SPFS (surface plasmon field-enhanced fluorescence spectroscopy) technology developed by Konica Minolta. The transaction amount for this asset acquisition has not been disclosed.

Konica Minolta has developed the world's first SPFS technology for highly sensitive detection of trace proteins. With this technology, medical institutions can measure disease biomarkers in a short time through a simple operation based on insertion of a dedicated cartridge into the measuring device. Otsuka expects to develop an antigen-based measurement system with a level of sensitivity close to that of a PCR (polymerase chain reaction) test.

Otsuka considers the steps from diagnosis to treatment as part of a continuum and thereby aims to contribute to better health for people worldwide through diagnostic drugs. Through the acquisition of this SPFS technology higher diagnostic sensitivity is expected through Otsuka's development of unique biomarkers that have not been detectable by conventional testing methods. The technology is also expected to be used to support the research and development of innovative drugs within the Otsuka group of companies.